IMA4 Antibody

What is the iMab antibody and what are its primary binding targets?

iMab is an anti-CD4 antibody that shows a broad spectrum of antiviral effects and prevents HIV-1 infection in a non-competitive manner. The antibody selectively recognizes and binds to the CD4 receptor on host cells. Additionally, recent research has demonstrated that iMab can also selectively bind to i-Motifs, which are quadruplex nucleic acid conformations that form in cytosine-rich regions . This dual binding capability makes iMab particularly valuable in both HIV research and nucleic acid structure studies.

How does the binding specificity of iMab differ from other antibodies?

The iMab antibody exhibits highly selective binding properties. Unlike many antibodies with single target specificity, iMab demonstrates selectivity not only for the CD4 receptor protein but also for both intramolecular and intermolecular i-Motif structures in nucleic acids. Recent studies using NMR have confirmed that iMab can recognize C-rich sequences that form intermolecular i-Motifs, which was previously contested in the scientific literature . This dual specificity makes iMab unique among antibodies and particularly valuable for multiple research applications.

What buffer conditions are critical when designing experiments with iMab antibody?

Buffer composition significantly influences the selectivity of iMab antibody binding, particularly when studying i-Motif structures. Recent research has demonstrated that the composition of buffers used during binding and washing steps strongly affects the selectivity of antibody binding to different DNA structures . When designing experiments with iMab, researchers should optimize:

• pH conditions (especially important as i-Motifs are pH-dependent structures)

• Ionic strength of binding buffers

• Blocking reagents to prevent non-specific interactions

• Washing buffer composition to maintain specific interactions while removing non-specific binding

Careful optimization of these parameters is essential to ensure that observed binding represents true biological interactions rather than experimental artifacts.

How should DNA concentration be optimized when using iMab for i-Motif detection?

DNA concentration is a critical parameter when using iMab for the detection of i-Motif structures. At high concentrations, C-rich DNA sequences can form intermolecular i-Motifs even under conditions where intramolecular i-Motifs might not be stable. This phenomenon has been confirmed by NMR studies showing that several previously reported C-rich sequences, which were not expected to form i-Motifs, actually form intermolecular i-Motifs that are selectively recognized by iMab . Researchers should:

• Titrate DNA concentrations to determine optimal conditions

• Consider both intramolecular and intermolecular i-Motif formation

• Include appropriate controls at matching concentrations

• Verify structural conformations using complementary techniques like NMR or circular dichroism

What are the recommended ELISA protocols for determining iMab binding activity?

Based on published research methodologies, the following ELISA protocol has been successfully used to evaluate iMab binding activity:

• Coat ELISA plates with the target protein (e.g., CD4 receptor protein) at appropriate concentration

• Wash with PBST and block unoccupied sites

• Add serial dilutions of purified iMab antibody (100 μL/well) and incubate for 30 min at 37°C

• Wash thoroughly and add 100 μL of HRP-conjugated goat anti-human IgG antibody

• Incubate at 37°C for 30 min

• Wash five times and add 100 μL of TMB substrate

• Incubate at room temperature in the dark for 15 min

• Stop the reaction with 2M H₂SO₄ solution and measure absorbance at 450 nm

• Run all samples in triplicate

• Determine the relative affinity by measuring the concentration required to achieve EC₅₀

This methodology allows for quantitative assessment of binding activity and facilitates comparison between different experimental conditions.

How can researchers characterize the domain-specific binding of iMab using advanced techniques?

Advanced characterization of iMab domain-specific binding can be performed using a combination of techniques:

• Domain Detection ELISAs: Develop domain-specific ELISAs that can detect binding to specific epitopes or domains. This approach has been successfully used in characterizing anti-drug antibody responses to bispecific antibodies like cibisatamab .

• Biolayer Interferometry Analysis: This technique can provide detailed kinetic information about antibody-antigen interactions, including association and dissociation rates. Studies have shown this method can effectively characterize binding features, revealing fast association and slow dissociation kinetics .

• Pull-down and Western Blot Assays: These assays can be particularly useful for examining the binding of iMab to nucleic acid structures under different buffer conditions .

• Nuclear Magnetic Resonance (NMR): NMR analysis can provide structural confirmation of i-Motif formation and antibody binding specificity, as demonstrated in recent studies validating iMab selectivity for intermolecular i-Motifs .

How should researchers interpret contradictory results regarding iMab binding specificity?

Recent literature has reported seemingly contradictory results regarding iMab binding specificity, particularly its ability to recognize C-rich sequences regardless of i-Motif conformation. When faced with such contradictions, researchers should:

• Critically evaluate experimental conditions: Buffer composition, DNA concentration, and washing protocols significantly affect binding specificity, as demonstrated in recent studies .

• Consider intermolecular vs. intramolecular structures: Evidence from NMR studies shows that C-rich sequences can form intermolecular i-Motifs even when intramolecular structures are not expected, which explains some apparent contradictions in binding data .

• Use multiple analytical techniques: Combining binding assays (ELISA, pull-down) with structural confirmation methods (NMR, CD spectroscopy) provides more robust evidence of binding specificity.

• Control for non-specific binding: Implement rigorous controls to distinguish specific from non-specific interactions, particularly when working with nucleic acids.

• Consider antibody concentration effects: High antibody concentrations may detect lower-affinity interactions that are not biologically relevant.

What factors contribute to loss of iMab detection in complex biological samples?

When working with iMab in complex biological samples, several factors can contribute to loss of detection sensitivity:

• Development of anti-drug antibodies (ADAs): Similar to observations with other therapeutic antibodies, anti-drug antibody responses can interfere with detection and function. Characterization of such responses typically shows an initial IgM response followed by a stronger IgG response with higher titer .

• Domain-specific interference: Binding to specific domains of the antibody can be blocked in complex biological matrices. For example, in studies of bispecific antibodies, patient-derived ADAs were found to be mainly directed to specific domains, interfering with target binding .

• Buffer interference: Components in biological samples may alter the optimal buffer conditions for iMab binding, particularly for pH-sensitive i-Motif detection .

• Competing binding partners: Biological samples contain numerous potential binding partners that may compete with intended targets.

• Protein degradation: iMab stability may be compromised in certain biological matrices, leading to reduced detection.

How can iMab be incorporated into multispecific antibody designs for enhanced functionality?

iMab has been successfully incorporated into multispecific antibody designs, particularly for HIV research. The following engineering approach has been validated:

• DVD-Ig Format Engineering: The variable domains of iMab (anti-CD4) and other antibodies like PRO140 (anti-CCR5) can be fused with connecting G4S linkers (GGGGSGGGGS) on both N and C termini of a full IgG1 antibody .

• ScFv Fusion: Additional specificity can be added by connecting single-chain variable fragments (scFvs) to the C terminus of the CH3 domain via GGGGSGGGGS linkers .

• Balanced Chain Design: For optimal expression and stability, the heavy and light chains should be carefully designed with balanced domain compositions. Cotransfection with a 1:1.5 molar ratio of heavy chain to light chain plasmids has been shown to yield good results in HEK293F expression systems .

This approach has been used to generate trispecific antibodies (iMab + PRO140 + third specificity) that maintain favorable binding activity to both CD4 receptor and CCR5 co-receptor while gaining additional binding properties to HIV-1 antigens .

What expression systems are most effective for producing functional iMab and its derivatives?

Based on documented research, the following expression systems have proven effective for producing functional iMab and its engineered derivatives:

• HEK293F Cells: This human cell line has been successfully used for the expression of trispecific antibodies incorporating iMab. Transfection using a 1:1.5 molar ratio of heavy chain to light chain plasmids, followed by Protein A purification, yields highly purified antibodies with good activity .

• Chinese Hamster Ovary (CHO) Cells: While not specifically mentioned for iMab in the provided search results, CHO cells are commonly used for therapeutic antibody production, as seen with other antibodies like trastuzumab deruxtecan .

The choice of expression system should be guided by the intended application, with mammalian expression systems generally preferred for maintaining proper glycosylation and folding of complex antibody formats.

How does iMab compare with other anti-CD4 antibodies in HIV research applications?

iMab distinguishes itself from other anti-CD4 antibodies in HIV research through several key characteristics:

• Non-competitive Inhibition Mechanism: iMab prevents HIV-1 infection in a non-competitive manner, which differs from antibodies that directly compete with the virus for CD4 binding .

• Complementary Activity with Co-receptor Inhibitors: iMab works synergistically with co-receptor inhibitors like PRO140 (anti-CCR5), making it valuable in multispecific antibody design .

• Breadth of Antiviral Effects: iMab has demonstrated a broad spectrum of antiviral effects against diverse HIV-1 strains .

• Adaptability to Multispecific Formats: The antibody has been successfully incorporated into trispecific antibody designs that show excellent antiviral effect in vivo, maintaining favorable binding activity when combined with other specificities .

These properties make iMab particularly valuable for both fundamental HIV research and the development of novel therapeutic approaches.

What are the critical controls needed when using iMab for i-Motif detection in cellular contexts?

When using iMab for i-Motif detection in cellular contexts, researchers should implement the following critical controls:

• pH Controls: Since i-Motifs are pH-dependent structures, include samples prepared at varying pH conditions to confirm the specificity of detection in the expected pH range .

• Sequence Specificity Controls: Include C-rich sequences known to form i-Motifs (positive controls) and sequences that cannot form these structures (negative controls) .

• Structure Verification: Use complementary techniques like NMR or circular dichroism to verify the presence of i-Motif structures in parallel samples .

• Buffer Composition Controls: Test multiple buffer compositions during binding and washing steps to ensure observed signals are not artifacts of specific buffer conditions .

• Antibody Specificity Controls: Include control antibodies of the same isotype but different specificity to rule out non-specific binding.

• DNA Concentration Series: Test multiple DNA concentrations to distinguish between intramolecular and intermolecular i-Motif formation .

• Competition Assays: Perform competition experiments with unlabeled i-Motif-forming sequences to verify binding specificity.

How can researchers troubleshoot loss of iMab binding activity in experimental settings?

When experiencing loss of iMab binding activity, researchers should systematically investigate the following factors:

• Antibody Degradation: Check the integrity of the antibody using SDS-PAGE or size exclusion chromatography. Store antibodies according to manufacturer recommendations (typically -20°C or -80°C, avoiding repeated freeze-thaw cycles).

• Buffer Optimization: As demonstrated in recent research, buffer composition significantly affects iMab binding selectivity, particularly for i-Motif detection . Systematically test different buffer compositions, focusing on:

  • pH (especially critical for i-Motif stability)

  • Ionic strength

  • Detergent type and concentration

  • Blocking reagents

• Target Conformation: Ensure that the target (CD4 protein or i-Motif DNA) maintains its proper conformation under experimental conditions.

• Interfering Substances: Identify and eliminate potential interfering substances in the sample that might compete for binding or denature the antibody.

• Detection System Issues: Verify the functionality of detection reagents (e.g., secondary antibodies, HRP, TMB substrate) using positive controls.

• Experimental Conditions: Review incubation times, temperatures, and washing protocols, which can significantly impact binding efficiency.

What strategies can improve the specificity of iMab in complex experimental settings?

To improve iMab specificity in complex experimental settings, researchers should consider implementing the following strategies:

By systematically implementing these strategies, researchers can significantly improve the specificity of iMab in their experimental systems.

What emerging applications are being developed for iMab beyond current research uses?

Based on current research trends, several emerging applications for iMab are being developed:

• Expanded Multispecific Antibody Platforms: Building on successful trispecific antibody designs incorporating iMab, researchers are exploring additional combinations to target multiple epitopes simultaneously for enhanced therapeutic potential .

• Cellular Process Investigation: The ability of iMab to detect i-Motifs in cellular contexts is opening new avenues for investigating the role of these DNA structures in gene regulation and cell cycle progression .

• Diagnostic Applications: The selective binding properties of iMab may enable new diagnostic approaches for detecting specific DNA conformations associated with disease states.

• Targeted Drug Delivery: Incorporation of iMab specificity into drug delivery systems could enable targeting to cells expressing CD4 or tissues with abundant i-Motif structures.

• Structural Biology Tools: iMab is becoming an important tool for studying the formation and dynamics of i-Motif structures under various conditions, contributing to our understanding of nucleic acid structural biology .

What technical advances might address current limitations in iMab research applications?

Several technical advances could address current limitations in iMab research applications: